Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Point’s Bet on Healthcare Sector Paid Off?

After having increased the position by 37% during the second quarter, Opus Point further added 11,437 shares of AstraZeneca plc (ADR) (NYSE:AZN) to its stake in the following three months, and disclosed a $3.94 million stake containing 120,000 shares in its latest 13F filing. Meanwhile, the stock gained 10.3% during the third quarter. The number of funds from our database long AstraZeneca plc (ADR) (NYSE:AZN) increased by 33% to 24 during the second quarter. Among the funds, tracked by Insider Monkey, Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital had the most valuable position in AstraZeneca plc (ADR) (NYSE:AZN), worth close to $244.6 million at the end of June. Sitting at the No. 2 spot was Renaissance Technologies holding a $180.1 million stake. Remaining peers that hold long positions consist of Israel Englander’s Millennium Management, D. E. Shaw’s D E Shaw and Dmitry Balyasny’s Balyasny Asset Management.

On the other hand, Opus Point closed its stake in Medivation Inc (NASDAQ:MDVN) during the third quarter amid a 35.1% jump registered by the stock during the same period. Previously, the fund had held 51,561 shares worth $3.11 million at the end of June. There were 65 funds tracked by us bullish on Medivation Inc (NASDAQ:MDVN) heading into the third quarter, up by 33% over the quarter. More specifically, The largest stake in Medivation Inc (NASDAQ:MDVN) was held by York Capital Management, which reported holding $305.9 million worth of stock as of the end of June. was followed by Tourbillon Capital Partners with a $284.9 million position. Other investors bullish on the company included Knoll Capital Management, Pentwater Capital Management, and Eton Park Capital.

Disclosure: none